A director at Dr. Lal PathLabs Ltd sold 20,000 shares at 2,558.519INR and the significance rating of the trade was 61/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...
DR LAL PATHLABS (IN), a company active in the Health Care Providers industry, slightly increases its general evaluation. The independent financial analyst theScreener just confirmed the stock market behaviour of the title as moderately risky. At the fundamental level, theScreener confirms the rating of 0 out of 4 stars; given the more favourable environment, the title's overall rating is upgraded to Neutral even if it remains under pressure. As of the analysis date March 1, 2022, the closing pri...
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
Q3FY20 result highlights DLPL reported sales of Rs3.3b (+12% yoy; Q2:Rs3.7b) inline with est led by a 12% vol growth and flat realization growth Realisation/patient grew 0.7% yoy to Rs688 (est Rs690) while patient volume growth was 12% vs est 11%. Mgt cited a higher contribution from cities outside Delhi-NCR as the primary driver for volume growth. While Delhi-NCR growth softened sharply to 2%, RoI volumes grew 19.8% and accounted for 61.2% of total volumes (vs 59% in Q2). Mgt attributed ha...
Q2FY20 result highlights DLPL reported sales of Rs3.6b (+15% yoy; Q1:Rs3.4b) inline with est led by a 3% yoy realization growth and 10% vol growth Realisation/patient (3% growth yoy to Rs684) was partially offset by a lower than expected vol growth (10% yoy vs est 12% growth). Mgt cited a higher contribution from cities outside Delhi-NCR as the primary driver for volume growth. While Delhi-NCR volumes grew 11%, RoI volumes grew 20.2% and accounted for 59% of total volumes (vs 57% last year)....
Q1FY20 result highlights DLPL reported sales of Rs3.4b (+15% yoy; Q4:Rs3b) vs est of Rs 3.3bn led by a +16% volume growth (4.9m patients tested; est 4.8m) Volume improvement was partially offset by a dip in realisation/patient to Rs684 (-1% yoy) vs our est of Rs696. Mgt cited a higher contribution from cities outside Delhi-NCR for increase in volumes as well as reduced realization. While Delhi-NCR volumes grew 11%, RoI volumes grew 19%. GMs came in higher at 78.8% (78.3% in Q4) vs our est o...
Event DLPL has acquired 70% equity stake in a couple of Indore labs Key highlights DLPL has acquired a majority stake in a company comprising of two Indore based labs owned by Vinita Kothari and Sushila Dalal for a consideration of < Rs~0.5bn (FY19 rev – Rs135mn). This deal strengthens its presence in Madhya Pradesh – relatively untapped market. Earlier in April, DLPL had also acquired a pathology lab (Bawankar Pathology) in Bhandara, Maharashtra for Rs50mn on a slump sale basis. (FY18 rev...
Q3FY19 result highlights DLPL reported sales of Rs2.9b (+11% yoy; Q2 Rs3.17bn) led by +17% volume growth (4.3mn samples; est 4.5m) vs est of +14% yoy. Patients tested grew +12% yoy. Mgt cited lower temperatures prevailing in North India and shift of festive season to Q3 for lower volumes. Realization / patient inched up qoq to Rs683 from Rs669 in Q2 which aided revenue growth. Mgt cited reduction in promotional activities in Eastern region as a key driver for realization improvement. GMs ca...
Dr Lal PathLabs (DLPL) is one of the largest diagnostic chains in India with a pan India presence. The fragmented but steadily consolidating Indian diagnostics industry is estimated to post 14-16% CAGR over FY18-20E implying significant opportunities for stronger organised players like DLPL. DLPL’s strong brand franchise, focus on service & quality and a broad basket of test offerings have enabled the company to create a leading position in North India. The company seeks to replicate this succes...
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.